Leronlimab (PRO 140) 是一种人源化 IgG4 抗 CCR5 单克隆抗体。leronlimumab 抑制 CCR 介导的 HIV-1 病毒和小鼠肿瘤模型肺转移。Leronlimab 可用于 HIV 非酒精性脂肪性肝炎 (NASH) 和癌症的研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

Anti-CCR5 / CD195 Reference Antibody (leronlimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-CCR5 / CD195 Reference Antibody (leronlimab) is more than 95%, determined by SEC-HPLC.

Human CCR5 His EGFP HEK293 cells were stained with Anti-CCR5 / CD195 Reference Antibody (leronlimab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.3073 ug/mL.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.